AdductNE LLC Profile last edited on: 3/2/2022
CAGE: 895F2
UEI: NPCHEVDTMNM6
Business Identifier: Increasing tumor residualization of receptor-targeted constructs using protease inhibitors 
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
Location Information
1604 North 154th Street
Omaha, NE 68154
Omaha, NE 68154
| (402) 637-1002 |
| N/A |
| N/A |
Location: Single
Congr. District: 02
County: Douglas
Congr. District: 02
County: Douglas
Public Profile
Arguing that targeted radionuclide therapeutics (TRTs) allows for the selective delivery of therapeutic radiation doses to tumors, while at the same time reducing non-target toxicities, AdductNE LLC is structured around addressing approaches selectively to increase the tumor residualization of receptor-targeted constructs using protease inhibitors. The firm's proprietary tumor-residualizing TRTs selectively localize in the tumors and form irreversible, high-molecular-weight adducts. Principalsof the firm have demonstrated that utilization of irreversible, protease inhibitors greatly increase the tumor-residualization of two TRT platforms the firm is currently exploring for clinical translation.
Extent of SBIR involvement
Synopsis: Awardee Business Condition
Employee Range
1-4Revenue Range
Less than .5MVC funded?
NoPublic/Private
Privately HeldStock Info
----IP Holdings
N/AAwards Distribution by Agency
Most Recent SBIR Projects
| Year | Phase | Agency | Total Amount | |
|---|---|---|---|---|
| 2021 | 1 | NIH | $400,000 | |
| Project Title: Development of a Targeted Radiotherapeuitc for Pancreatic Ductal Adenocarcinoma | ||||
Key People / Management
Jered C Garrison -- President
Company News
There are no news available.
